BR112018012177A2 - ?moduladores de hidantação de canais kv 3? - Google Patents
?moduladores de hidantação de canais kv 3?Info
- Publication number
- BR112018012177A2 BR112018012177A2 BR112018012177A BR112018012177A BR112018012177A2 BR 112018012177 A2 BR112018012177 A2 BR 112018012177A2 BR 112018012177 A BR112018012177 A BR 112018012177A BR 112018012177 A BR112018012177 A BR 112018012177A BR 112018012177 A2 BR112018012177 A2 BR 112018012177A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydration
- modulators
- channel
- compounds
- prophylaxis
- Prior art date
Links
- 230000036571 hydration Effects 0.000 title 1
- 238000006703 hydration reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522179.9A GB201522179D0 (en) | 2015-12-16 | 2015-12-16 | Novel compounds |
| PCT/GB2016/053958 WO2017103604A1 (en) | 2015-12-16 | 2016-12-16 | Hydantoin modulators of kv3 channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018012177A2 true BR112018012177A2 (pt) | 2018-11-27 |
Family
ID=55274838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018012177A BR112018012177A2 (pt) | 2015-12-16 | 2016-12-16 | ?moduladores de hidantação de canais kv 3? |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200377485A1 (https=) |
| EP (1) | EP3390394B1 (https=) |
| JP (1) | JP7036725B2 (https=) |
| CN (1) | CN108430995A (https=) |
| BR (1) | BR112018012177A2 (https=) |
| GB (1) | GB201522179D0 (https=) |
| WO (1) | WO2017103604A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| EP3555073A1 (en) | 2016-12-16 | 2019-10-23 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| KR102854594B1 (ko) | 2018-10-16 | 2025-09-02 | 오티포니 세라피틱스 리미티드 | 신규한 화합물 |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| AR116898A1 (es) | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| JP2022529663A (ja) | 2019-04-26 | 2022-06-23 | ハー・ルンドベック・アクチエゼルスカベット | Ｋｖ３カリウムチャネル活性化薬としてのアリールスルホニルチオフェンカルボキサミド及びアリールスルホニルフランカルボキサミド |
| WO2020216920A1 (en) | 2019-04-26 | 2020-10-29 | H. Lundbeck A/S | N-((heteroaryl)methyl)-1-tosyl-1h-pyrazole-3-carboxamide derivatives as kv3 potassium channel activators for treating neurological and psychiatric disorders |
| BR112022013339A2 (pt) * | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| EP3901152A1 (en) * | 2020-04-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Kv3 enhancers for the treatment of cognitive disorders |
| KR20240046748A (ko) * | 2021-08-10 | 2024-04-09 | 오티포니 세라피틱스 리미티드 | 칼륨 채널 조절제 |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6299383A (ja) * | 1985-10-28 | 1987-05-08 | Tokuyama Soda Co Ltd | エ−テル化合物の製造方法 |
| EP1534276B1 (en) | 2002-09-05 | 2008-11-05 | Medivir AB | Non-nucleoside reverse transcriptase inhibitors |
| US20050080100A1 (en) | 2003-10-09 | 2005-04-14 | Pfizer Inc | Pyridylamino compounds and methods of use thereof |
| EP1845087A1 (en) | 2006-04-14 | 2007-10-17 | Mutabilis SA | Hydroxyphenyl derivatives and biological applications thereof |
| DK2563776T3 (en) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Relations that modulate intracellular calcium |
| EA023768B1 (ru) * | 2010-12-06 | 2016-07-29 | Отифони Терапеутикс Лимитед | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ |
| US20120316182A1 (en) * | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AR087309A1 (es) * | 2011-07-27 | 2014-03-12 | Glaxo Group Ltd | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis |
| US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| CN104471041A (zh) * | 2012-06-06 | 2015-03-25 | 范德比尔特化学品有限责任公司 | 节油润滑油 |
| WO2015031036A1 (en) * | 2013-08-26 | 2015-03-05 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
-
2015
- 2015-12-16 GB GBGB1522179.9A patent/GB201522179D0/en not_active Ceased
-
2016
- 2016-12-16 EP EP16816359.0A patent/EP3390394B1/en not_active Not-in-force
- 2016-12-16 WO PCT/GB2016/053958 patent/WO2017103604A1/en not_active Ceased
- 2016-12-16 BR BR112018012177A patent/BR112018012177A2/pt not_active IP Right Cessation
- 2016-12-16 JP JP2018531529A patent/JP7036725B2/ja not_active Expired - Fee Related
- 2016-12-16 US US16/061,557 patent/US20200377485A1/en not_active Abandoned
- 2016-12-16 CN CN201680074553.9A patent/CN108430995A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108430995A (zh) | 2018-08-21 |
| EP3390394B1 (en) | 2022-05-25 |
| GB201522179D0 (en) | 2016-01-27 |
| JP7036725B2 (ja) | 2022-03-15 |
| US20200377485A1 (en) | 2020-12-03 |
| WO2017103604A1 (en) | 2017-06-22 |
| EP3390394A1 (en) | 2018-10-24 |
| JP2019502696A (ja) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018012177A2 (pt) | ?moduladores de hidantação de canais kv 3? | |
| EP3545647A4 (en) | REGULATION OF CONFIDENT BLOCKCHAIN TRANSACTIONS | |
| UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| MX383652B (es) | Moduladores de la vía de estrés integrada. | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| AU2016278853A8 (en) | Petrolatum-based compositions comprising cationic biocides | |
| MX383880B (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CL2016000106A1 (es) | Sulfonamidas como moduladores de canales de sodio. | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX384833B (es) | Inhibidores de tirosina quinasa de bruton | |
| CR20200089A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MX391040B (es) | Formulacion de alta concentracion. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| MX385578B (es) | Moduladores de canales de kv3 para tratar dolor. | |
| CO2019014647A2 (es) | Composiciones inmunogénicas | |
| EA201992147A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX374728B (es) | MODULADORES DE ROR GAMMA (RORy). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |